Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/IIa Open-label Study, to Evaluate Safety, Tolerability, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Gastric or Gastro-esophageal (GEJ) Adenocarcinoma

NCT07680569 is registered in ClinicalTrials.gov with Kaohsiung Medical University Chung-Ho Memorial Hospital as lead sponsor.

NCT NCT07680569
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07680569 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/IIa Open-label Study, to Evaluate Safety, Tolerability, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Gastric or Gastro-esophageal (GEJ) Adenocarcinoma
Lead sponsor
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
December 31, 2027
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gc/gejc